ReachMD

Episodes 1-15 of 28

• • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Coy Heldermon, MD, PhD

    Peer

  • 

    

    Heather Lau, MD, MS

    Peer

  3

  

  RestartResume

  How Can We Prevent the Delayed Diagnosis of Type 1 Gaucher Disease?

  How Can We Prevent the Delayed Diagnosis of Type 1 Gaucher Disease?

• • 

    

    Charles Turck, PharmD, BCPS, BCCCP

    Peer

  • 

    

    Harry Paul Erba, MD, PhD

    Peer

  • 

    

    Uma Borate, MD, MS

    Peer

  0

  

  RestartResume

  Advances in AML: The Role of a Targeted Therapy in Current Treatment Paradigms

  Advances in AML: The Role of a Targeted Therapy in Current Treatment Paradigms

• • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Keith McCrae, MD

    Peer

  • 

    

    Terry B. Gernsheimer, MD

    Peer

  1

  

  RestartResume

  Immune Thrombocytopenia: Updated Practice Guidelines in an Evolving Treatment Landscape

  Immune Thrombocytopenia: Updated Practice Guidelines in an Evolving Treatment Landscape

• • 

    

    John J. Russell, MD

    Peer

  • 

    

    Fernando de Zarraga, MD

    Peer

  • 

    

    Raed Al-Rajabi, MD

    Peer

  3

  

  RestartResume

  Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer

  Exploring an Evidence-Based Treatment Pathway for Chemorefractory Wild-Type RAS Metastatic Colorectal Cancer

• • 

    

    Matt Birnholz, MD

    Peer

  • 

    

    Ralph V. Boccia, MD

    Peer

  • 

    

    James Bussel, MD

    Peer

  1

  

  RestartResume

  Expert Perspectives on Immune Thrombocytopenia

  Expert Perspectives on Immune Thrombocytopenia

• • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Suma Satti, MD

    Peer

  7

  

  RestartResume

  Exploring First-Line Treatment in Extensive-Stage Small Cell Lung Cancer

  Exploring First-Line Treatment in Extensive-Stage Small Cell Lung Cancer

• • 

    

    Ilene Galinsky BSN,MSN,ANP-C

    Peer

  1

  

  RestartResume

  Monitoring for Neutropenia in Acute Myeloid Leukemia 

  Monitoring for Neutropenia in Acute Myeloid Leukemia 

• • 

    

    Ilene Galinsky BSN,MSN,ANP-C

    Peer

  3

  

  RestartResume

  The Ramp-Up & Dosing of an Acute Myeloid Leukemia Therapy 

  The Ramp-Up & Dosing of an Acute Myeloid Leukemia Therapy 

• • 

    

    Matthew S. Davids, MD, MMSc

    Peer

  • 

    

    Andrew Souers, PhD

    Peer

  2

  

  RestartResume

  When Apoptosis Becomes Impaired: Targeting BCL-2

  When Apoptosis Becomes Impaired: Targeting BCL-2

• • 

    

    Paul Doghramji, MD

    Peer

  • 

    

    Alex Spira, MD, PhD, FACP

    Peer

  • 

    

    John Longshore, PhD, FACMG

    Peer

  1

  

  RestartResume

  Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape

  Spotlight on KRAS G12C: Biomarker Testing Considerations in the NSCLC Landscape
• 1

  

  RestartResume

  Impact of Hemoglobin S Polymerization on Sickle Cell Disease

  Impact of Hemoglobin S Polymerization on Sickle Cell Disease

• • 

    

    Ken H. Shain, MD, PhD

    Peer

  0

  

  RestartResume

  The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma

  The Role of a Triplet Regimen in Relapsed/Refractory Multiple Myeloma

• • 

    

    Harry Paul Erba, MD, PhD

    Peer

  1

  

  RestartResume

  Changing Our View of Acute Myeloid Leukemia in Older Adults

  Changing Our View of Acute Myeloid Leukemia in Older Adults

• • 

    

    Harry Paul Erba, MD, PhD

    Peer

  1

  

  RestartResume

  Therapeutic Targets in Acute Myeloid Leukemia

  Therapeutic Targets in Acute Myeloid Leukemia

• • 

    

    Matthew S. Davids, MD, MMSc

    Peer

  1

  

  RestartResume

  Measuring Depth of Remission in Chronic Lymphocytic Leukemia

  Measuring Depth of Remission in Chronic Lymphocytic Leukemia

• 1
• 2
• Next